|
|
 |
|
Viewing report
|
|
|
|
OTC Obesity in France
Euromonitor International, April 2010, Pages: 49
The main story in OTC obesity was the entrance of Alli by GlaxoSmithKline in 2009. According to trade press, this type of event only occurs every 10 years in the pharmaceuticals market, the last time being the launch of Viagra in Rx form. The launch of Alli triggered many articles in the media, heated reaction, criticism from experts and varied consumer opinion on Internet blogs and messageboards, which ultimately resulted in free advertising for the GlaxoSmithKline brand.
The OTC Obesity Products in France report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.
Product coverage:
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
- Get a detailed picture of the Consumer Health industry;
- Pinpoint growth sectors and identify factors driving change;
- Understand the competitive environment, the market’s major players and leading brands;
- Use five-year forecasts to assess how the market is predicted to develop.
.
Customers who bought this item also bought
Analgesics in France
Vitamins and Dietary Supplements in France
Slimming Products in France
Digestive Remedies in France
Wound Treatments in France
Cough, Cold and Allergy (Hay Fever) Remedies in France
Herbal/Traditional Products in France
Weight Management in France
Calming and Sleeping in France
Eye Care in France
|
|
|
|
